Introduction
============

Ischemic heart disease is the most common cause of death in patients with chronic kidney disease (CKD). CKD in acute coronary syndrome (ACS) is independently associated with increased morbidity and mortality.[@b1-ijnrd-9-005] Traditional and unique risk factors are prevalent putting patients with CKD at higher risk of developing coronary artery disease (CAD) and constitute challenges for the standard of care.[@b1-ijnrd-9-005] Despite recognizing this high-risk group, patients with CKD have been largely excluded from randomized controlled trials and management guidelines are not established.[@b1-ijnrd-9-005]

ACS diagnosis is based on the clinical presentation of ischemic symptoms, cardiac biomarkers, and electrocardiogram changes. Compared with general population, CKD patients commonly have atypical presentation as in elderly and diabetic; in addition, diagnostic markers have low predictive value since many patients have elevated troponins without having ACS.[@b1-ijnrd-9-005],[@b2-ijnrd-9-005]

In fact, CKD patients have better outcomes when evidence-based therapy is adopted.[@b2-ijnrd-9-005] Analysis of data from large clinical trials demonstrated that the implementation of invasive treatment is associated with better prognosis in patients with end-stage renal disease (ESRD) and moderate CKD. However, one study demonstrated that patients with ACS and low glomerular filtration rate (GFR) are less likely to receive invasive interventions, and if they received angiography, they may not undergo revascularization.[@b3-ijnrd-9-005],[@b4-ijnrd-9-005] It is not clear if these strategies would have similar risk--benefit profiles in the treatment of renal impaired patients. For example, in a review of randomized trials, antiplatelet therapy in patients with CKD had no significant reduction of cardiovascular events or death but had increased risk of major bleeding.[@b5-ijnrd-9-005] The risk of complications increases with the reduction in GFR, and patients on dialysis have the worst prognosis.[@b6-ijnrd-9-005]

Optimal therapy is yet to be defined. As such, ACS in CKD remains a challenge for the cardiologist. Significant data regarding inpatient care of patients with CKD and ESRD presenting with ACS come from Medicare and Medicare data reports available from the United States Renal Data System, which reported significant disparities in care in patients with CKD and ESRD.[@b7-ijnrd-9-005] Another report from the National Cardiovascular Data Acute Coronary Treatment and Intervention Outcomes Network Registry also reported that these disparities exist.[@b8-ijnrd-9-005]

The aim of this study was to evaluate differences in inpatient care among patients without CKD, patients with CKD stage III--V, and patients with ESRD requiring renal replacement therapy admitted to our institution with myocardial infarction (MI).

Materials and methods
=====================

Design and methodology
----------------------

This was a retrospective study including all patients admitted to Staten Island University Hospital with a diagnosis of MI between January 2005 and December 2012. Patients were excluded from the study if they had a diagnosis of acute kidney injury (AKI) at the time of presentation or had developed AKI during hospitalization but no CKD was present at the time of admission. The study was approved by the North Shore-LIJ Review Board. We identified these differences by reviewing medical records.

Patients were stratified into groups based on kidney function on admission, by estimating GFR using the Modification of Diet in Renal Disease equation, which uses the serum creatinine level at the time of presentation. It is defined as normal (GFR ≥60 mL/min/1.73 m^2^), moderate CKD (GFR 30--59 mL/min/1.73 m^2^), severe CKD (GFR \<30 mL/min/1.73 m^2^), and ESRD patients requiring dialysis. We hypothesized that there is no difference among the three groups of patients with respect to medical therapy and invasive cardiac procedures (such as cardiac catheterization and/or coronary artery bypass graft \[CABG\], if indicated), highlighting the need to apply optimal treatment strategies that high-risk patients would benefit from.

Statistical analysis
--------------------

The primary outcome variables were length of stay, invasive cardiac procedures (such as cardiac catheterization and/or CABG, if indicated), and use of medication.

For the analysis of length of stay, an analysis of covariance model comprised the fixed, categorical effects of the three groups of patients to be used, adjusting for potential confounding factors such as sex, age, race, and smoking status. Chi-square test was used to compare the proportions between nominal variables. Binary logistic analysis was used in order to determine associations between treatment modalities and comorbidities, and to account for possible confounding factors.

All statistical tests of significance were two-sided and were conducted at the 0.05 level of significance. All statistical analyses were conducted in SAS (Version 9.3, SAS Institute Inc., Cary, NC, USA).

Results
=======

Patient demographics and clinical characteristics
-------------------------------------------------

Three hundred and thirty-four patients were included, out of which 68.6% were males (mean age 67.2±13.9 years), 76% were Caucasian, 8.1% were African American, and 15.9% were Hispanic and other. One hundred and sixty-eight patients (50.3%) had ST-segment elevation MI, while 166 patients (49.7%) had non-ST-segment elevation MI; 39.2% had GFR \>60 mL/min/1.73 m^2^ on admission, 35.6% had CKD stage III--V, and 24% had ESRD on dialysis; 44.6% had diabetes, 73.1% had hypertension (HTN), 55.1% had dyslipidemia (DL), and 27.5% had congestive heart failure (CHF) ([Table 1](#t1-ijnrd-9-005){ref-type="table"}).

The length of stay for three cohorts (non-CKD, CKD stage III--V, and ESRD on hemodialysis \[HD\]) was 16, 17, and 15 days, respectively and was not statistically different.

In terms of medical management, treatment with aspirin, platelet inhibitors, angiotensin converting enzyme inhibitors, angiotensin receptor blockers, beta-blockers, and statins was achieved at high rates in our study and was similar irrespective of kidney function ([Table 2](#t2-ijnrd-9-005){ref-type="table"}).

However, coronary angiography was less likely to be performed in patients with ESRD compared with non-CKD (45.6% vs 93.9%) (*P*\<0.001). CABG was performed in 14.4% of non-CKD patients, 24.0% in CKD stage III--V, and 13.6% of patients on dialysis. It did not differ among the three groups (*P*=0.07). To note, ESRD and CKD stage III--V were more likely to go to CABG when catheterization was performed (30%) when compared with non-CKD patients (15%).

In binary logistics regression, medical therapy was not associated with a particular comorbidity with the exceptions of beta-blockers with HTN (*P*=0.020) and statins with CHF and DL (*P*=0.018 and 0.025, respectively). CABG was not associated with degree of CKD (*P*=0.074) (HTN, diabetes mellitus, and CHF showed a stronger association). Cardiac catheterization on the other hand carried the strongest association among all studied variables (*P*\<0.001). This association was maintained after adjusting for other comorbidities.

Discussion
==========

Patients with CKD and/or ESRD have a higher risk of CAD and morbidity/mortality from CAD, and should ideally receive current standard of care, as do patients with normal renal function. However, detailed reports including length of stay, differences in utilization of current evidence-based medical management, and invasive coronary intervention including coronary bypass surgery are not available on CKD and ESRD patients regarding CAD treatment.[@b9-ijnrd-9-005]

Many observations have reported discrimination of care for patients with CKD; studies showed that CKD patients were less likely to receive evidence-based therapy in ACS compared with patients without CKD as they are considered suboptimal candidates for aggressive management of their cardiac disease.[@b2-ijnrd-9-005],[@b9-ijnrd-9-005]

In our study, the exclusion criterion of AKI regardless of the presence of prior CKD was used to eliminate bias regarding the administration or withholding medication, intervention, and the length of stay. Medical therapy was achieved in high percentage in the three cohorts (non-CKD, CKD stage III--V, and ESRD on HD) and was comparable regardless of kidney function ([Figure 1](#f1-ijnrd-9-005){ref-type="fig"}).

As this study was observational and limited itself to the timeframe of hospitalization, we could only measure adherence to prescribing optimal therapy. A follow-up of the patients would shed the light on the complications related to therapy itself, which is beyond the scope of this study.

Percutaneous coronary revascularization improves long-term survival when compared with medical therapy,[@b9-ijnrd-9-005] yet we found that ESRD patients on HD were getting less catheterization than the other two groups (45.6% vs 75.8% and 93.9%) (*P*\<0.001). Unique risk factors were present in these patients putting them at once at high risk of CAD and of procedural complications.

The Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment, Thrombolysis in Myocardial Infarction-Study 25 substudy demonstrated that bleeding is increased by 50% for every 30 mL/min decreased in GFR.[@b1-ijnrd-9-005] CKD/ESRD patients are known to have platelet dysfunction leading to prolonged bleeding time, which can complicate invasive procedure in patients with ACS. Another consideration is the altered drug metabolism in patients with ESRD. There is a required dose adjustment in patients with CKD due to higher risk of medication-related adverse events. Although anticoagulant drugs are the mainstay of ACS management, their benefit is still retained in CKD patients, and they should be used with caution to prevent bleeding complications.

Contrast-induced nephropathy (CIN) is a well-known complication after cardiac catheterization. Patients with CKD are at higher risk for CIN from iodinated radiocontrast used for coronary angiography[@b10-ijnrd-9-005] and the risk is inversely proportional to GFR.[@b2-ijnrd-9-005] Volume expansion with normal saline was shown to be the most effective strategy to prevent and reduce CIN.

Moreover, ESRD patients have extended small vessel disease that we believe is frequently responsible for their ischemic heart disease. Thus, there will be less interventions to fix distal small lesion within calcified vessel. In addition, ESRD will frequently have type 2 MI (supply/demand myocardial infarction) in a setting of significant deconditioning precipitated by prevalent comorbidities.

It is due to those risks and other reasons that patients with CKD may receive less percutaneous coronary interventions (PCIs) and thus a less invasive treatment. Complications may lead to prolonged hospital stay and higher hospital mortality.[@b9-ijnrd-9-005]

CABG was performed in comparable percentage among the three cohorts; furthermore, CABG was more likely to be done when catheterization was performed in ESRD patients on HD.

No evidence-based guidelines are available to direct the care for patients on HD.[@b9-ijnrd-9-005] Either CABG surgery or PCI can be used to treat multivessel CAD. Treatment modalities are mostly based on experiences and opinions rather than evidences.[@b11-ijnrd-9-005]

Existing studies report a significantly higher postoperative morbidity (cardiovascular complications and rate of permanent HD) and early mortality among patients with CKD who underwent CABG when compared with patients with preserved kidney function.[@b11-ijnrd-9-005],[@b12-ijnrd-9-005]

When CABG and PCI were compared in CKD, observational studies reported conflicting results. While some observational studies reported long-term CABG mortality benefit over PCI despite a higher early risk of death and ESRD, other studies suggested comparable outcomes.[@b13-ijnrd-9-005]--[@b15-ijnrd-9-005] In a recent study, ESRD patients on HD with multivessel and/or left main disease had reduced risk of cardiac death, sudden death, and MI and any revascularization in 5-year follow-up when they underwent CABG compared with PCI. However, the risk of all-cause death was not different.[@b12-ijnrd-9-005],[@b16-ijnrd-9-005],[@b17-ijnrd-9-005]

Physicians are overcoming challenges based on individual cases. The current challenge is to study the CAD patient with CKD in prospective randomized trials to provide an evidence-based approach to therapy. In the absence of such information, aggressive control of CAD risk factors and timely intervention for symptomatic CAD is suggested.[@b9-ijnrd-9-005]

Conclusion
==========

In conclusion, there is no difference among the three groups of patients (patients without CKD, patients with CKD, and patients with ESRD) with respect to medical management. On the other hand, catheterization was achieved less in ESRD on HD when compared with non-CKD patients. These observations will help us to evaluate the reasons for these disparities. Furthermore, we hope to identify barriers to the current standard of care for CAD provided to the patients with CKD and ESRD.
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###### 

Descriptive analysis

  -----------------------------------------------------------------------------------------------------------
  Variable                                         Frequency (%)\
                                                   (± standard deviation)
  ------------------------------------------------ ----------------------------------------------------------
  Age                                              [\*](#tfn1-ijnrd-9-005){ref-type="table-fn"}67.2 (±13.9)

  Race                                             

   Caucasian                                       254 (76.05)

   African American                                27 (8.08)

   Hispanic                                        3 (0.9)

   Other                                           50 (14.97)

  Sex                                              

   Female                                          105 (31.4)

   Male                                            229 (68.6)

  ACS                                              

   NSTEMI                                          166 (49.7)

   STEMI                                           168 (50.3)

  Kidney disease                                   

   Non-CKD (eGFR \>60), mL/min/1.73m^2^            131 (39.2)

   CKD stage III--V (eGFR \<60), mL/min/1.73m^2^   119 (35.6)

   ESRD on HD                                      80 (24.0)

  Diabetes (type 2)                                149 (44.6)

  Hypertension                                     244 (73.1)

  Hypercholesterolemia                             184 (55.1)

  CHF                                              92 (27.5)
  -----------------------------------------------------------------------------------------------------------

**Note:**

Data presented as mean (± standard deviation).

**Abbreviations:** ACS, acute coronary syndrome; NSTEMI, non-ST-segment elevation myocardial infarction; STEMI, ST-segment elevation myocardial infarction; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; ESRD, end-stage renal disease; HD, hemodialysis; CHF, congestive heart failure.

###### 

Population characteristics, medications, and interventions distribution

  -----------------------------------------------------------------------------------------------------------------
                            Non-CKD (eGFR \>60)   CKD stage III--V\              ESRD on HD   Significance (χ^2^)
                                                  (eGFR \<60), mL/min/1.73m^2^                
  ------------------------- --------------------- ------------------------------ ------------ ---------------------
  CHF                       15 (11.4%)            49 (39.8%)                     30 (37.0%)   0.000

  Hyperlipidemia            68 (51.5%)            76 (61.8%)                     42 (51.2%)   0.182

  Hypertension              70 (53.0%)            105 (85.4%)                    72 (87.8%)   \<0.001

  Diabetes                  33 (25.0%)            64 (51.6%)                     52 (63.4%)   \<0.001

  Race                                                                                        0.003

   Caucasian                95 (73.6%)            106 (86.9%)                    57 (72.2%)   

   African American         16 (12.4%)            4 (3.3%)                       6 (7.6%)     

   Hispanic                 0 (0.0%)              0 (0.0%)                       3 (3.8%)     

   Other                    18 (14.0%)            12 (9.8%)                      13 (16.5%)   

  CABG                      19 (14.4%)            29 (24.0%)                     11 (13.6%)   0.074

  Cardiac catheterization   124 (93.9%)           91 (75.8%)                     36 (45.6%)   \<0.001

  ASA                       122 (96.1%)           90 (90.9%)                     67 (90.5%)   0.204

  Beta-blockers             115 (90.6%)           89 (89.9%)                     69 (93.2%)   0.729

  Platelet inhibitors       109 (86.5%)           76 (77.6%)                     54 (74.0%)   0.067

  ACE inhibitors/ARB        70 (55.1%)            47 (47.5%)                     32 (43.2%)   0.232

  Statins                   121 (95.3%)           83 (83.8%)                     65 (87.8%)   0.017
  -----------------------------------------------------------------------------------------------------------------

**Abbreviations:** CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; ESRD, end-stage renal disease; HD, hemodialysis; CHF, congestive heart failure; CABG, coronary artery bypass graft; ASA, aspirin; ACE, angiotensin converting enzyme; ARB, angiotensin receptor blockers.
